Pioglitazone 15 mg Tablet Franchise in Mumbai Maharashtra

Antidiabetic PCD Pharma Opportunities in Delhi NCR

Piobot 15 Tablet Supply for Hospitals in Chennai Tamil Nadu

Pioglitazone 15 mg Tablet PCD Franchise in Kolkata West Bengal

Diabetes Care Medicine Distribution in Bangalore Karnataka
Pioglitazone Tablet Export and Third-Party Manufacturing in Hyderabad Telangana

Home/Products /pioglitazone-15-mg-tablet

Piobot 15 Tablet

Composition : Pioglitazone (15mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Piobot 15 Tablet contains Pioglitazone 15 mg, a thiazolidinedione-class oral antidiabetic drug that helps improve insulin sensitivity in the body. It effectively controls blood sugar levels in type 2 diabetes mellitus patients by enhancing glucose uptake in muscle and adipose tissue while reducing hepatic glucose production.

This medication is commonly prescribed as part of combination therapy with other oral antidiabetics like Metformin or Sulfonylureas to achieve optimal glycemic control. It supports long-term management of diabetes and helps reduce the risk of complications such as neuropathy, retinopathy, and cardiovascular disease.

Belonging to the antidiabetic and endocrinology segment, Piobot 15 Tablet is widely trusted by physicians for its sustained efficacy and tolerability. It offers a stable market opportunity for hospitals, clinics, and pharmacy distributors due to its consistent prescription demand.

For PCD pharma franchise partners, third-party manufacturers, and exporters, Piobot 15 Tablet represents a high-demand, low-return-risk product ideal for expanding business portfolios in the diabetes care domain. Its clinical reliability and profitability make it a cornerstone product in any antidiabetic range.


Read More

About the Product

Piobot 15 Tablet contains Pioglitazone 15 mg, a thiazolidinedione-class oral antidiabetic drug that helps improve insulin sensitivity in the body. It effectively controls blood sugar levels in type 2 diabetes mellitus patients by enhancing glucose uptake in muscle and adipose tissue while reducing hepatic glucose production.

This medication is commonly prescribed as part of combination therapy with other oral antidiabetics like Metformin or Sulfonylureas to achieve optimal glycemic control. It supports long-term management of diabetes and helps reduce the risk of complications such as neuropathy, retinopathy, and cardiovascular disease.

Belonging to the antidiabetic and endocrinology segment, Piobot 15 Tablet is widely trusted by physicians for its sustained efficacy and tolerability. It offers a stable market opportunity for hospitals, clinics, and pharmacy distributors due to its consistent prescription demand.

For PCD pharma franchise partners, third-party manufacturers, and exporters, Piobot 15 Tablet represents a high-demand, low-return-risk product ideal for expanding business portfolios in the diabetes care domain. Its clinical reliability and profitability make it a cornerstone product in any antidiabetic range.


Common side effects may include weight gain, edema (swelling), headache, and muscle pain. In rare cases, it may cause fluid retention, heart failure, or liver dysfunction. Report any symptoms such as unusual tiredness, yellowing of the skin, or rapid weight gain to your doctor immediately.

Piobot 15 Tablet is indicated for the management of type 2 diabetes mellitus in adults, especially those whose blood sugar levels are not adequately controlled by diet, exercise, or other oral antidiabetic agents. It helps in reducing insulin resistance and improving metabolic balance.

Take Piobot 15 Tablet as prescribed by your healthcare provider, preferably at the same time each day. Regular monitoring of blood glucose, liver function, and weight is essential. Inform your doctor if you have a history of heart disease, liver problems, or bladder cancer before starting treatment.

Store Piobot 15 Tablet in a cool, dry place below 25°C, protected from light and moisture. Keep it tightly closed and out of reach of children.

Get in Touch